Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. - Wikidata - wikimedia - TriplyDB

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

http://www.wikidata.org/entity/Q37178234

about

Farletuzumab in lung cancer Targeted immune therapy of ovarian cancer Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy Cytochrome C encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy Immunity and immune suppression in human ovarian cancer.Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.Monoclonal antibodies in gynecological cancer: a critical point of view.Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.Intraoperative imaging in ovarian cancer: fact or fiction?Prospects in folate receptor-targeted radionuclide therapy Strategy to prevent drug-related hypersensitivity in folate-targeted hapten immunotherapy of cancer Farletuzumab in epithelial ovarian carcinoma.Current treatment and clinical trials in ovarian cancer.Membrane proteins: the key players of a cancer cell.Clinical translation of folate receptor-targeted therapeutics.The Role of the Immune System in Ovarian Cancer and Implications on Therapy.Nuclear medicine for imaging of epithelial ovarian cancer.Physicochemical Evaluation of Lyophilized Formulation of p-SCN-Bn-DOTA- and p-SCN-Bn-DTPA-rituximab for NHL Radio Immunotherapy.Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.

P2860

Q26997008-09878262-EFC4-4F9B-9A59-192C2860691D Q28082828-AD2CC6E0-E0A1-4F21-BE02-C1B4FC9C9221 Q28397980-12C27FCA-82AE-48E6-82DE-9B29869328F1 Q30390185-FDCB35B2-8049-4302-8C93-72B7DFFD6A7F Q35138135-060B1456-F08F-463B-B4AE-3AF3E2C92728 Q35552059-D3B1036F-AA6D-469C-B08F-375847142587 Q35659915-C11F291F-8265-4154-92FB-FBC365EEAEE0 Q36361160-808D5162-C6A9-4E61-822D-CE5B19C91B84 Q37149571-0EE7E3A4-548E-4413-ACDB-4CA08C3B4649 Q37193061-F550E1A0-6A53-40C9-B059-6D7388F60D6E Q37378084-D215FF04-3C52-4094-9A24-2A14E390F039 Q37679219-C3AEC4DF-F29E-460D-A414-42071EF7C198 Q37724199-3E4F30B5-7BC9-450D-BD75-5CF590B95EB7 Q37898014-CFF83B5F-2E54-4B62-8686-67EBAE03CB02 Q38015901-5D10D6A6-94A7-4A73-9B69-8F2C83E6201C Q38715211-BB51FE13-E1CA-4979-A8B6-F8262059B659 Q38777588-5D9095F9-B2E7-4695-A149-D4F56022324D Q42355121-D9DC1E94-CE14-4911-A7EB-CA511A999196 Q47926770-E3318A88-748C-4A7C-9738-D81AB3D621A1

P2860

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

http://www.wikidata.org/entity/Q37178234

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Preclinical radioimmunotargeti ...... body conjugate DOTA-MORAb-003.

@en

Preclinical radioimmunotargeti ...... body conjugate DOTA-MORAb-003.

@nl

type

label

Preclinical radioimmunotargeti ...... body conjugate DOTA-MORAb-003.

@en

Preclinical radioimmunotargeti ...... body conjugate DOTA-MORAb-003.

@nl

prefLabel

Preclinical radioimmunotargeti ...... body conjugate DOTA-MORAb-003.

@en

Preclinical radioimmunotargeti ...... body conjugate DOTA-MORAb-003.

@nl

P1433

Q37178234-989069C1-A058-49E4-96B0-BB4E6FAC6C0D

P1476

Q37178234-2AF77AC0-389F-4D0E-8D06-4FFC2D6143E0

P2093

Q37178234-14234C1B-AB9B-496B-AA0E-13679D2D6C50

Q37178234-1C04C84B-297E-40FE-BF43-E6D33CFC94E8

Q37178234-583CF58E-DD3E-441B-8FD0-5999DF7F2107

Q37178234-87FFFECA-C2BA-4DA1-968E-5B669D25B184

Q37178234-8CB6C2FB-1405-49D6-8143-A68612867E0E

Q37178234-9708709E-2D23-4F36-B257-0BA9EB46E49B

P2860

Q37178234-03A1FD6A-2527-4F5A-A704-B9DF6B69C1DF

Q37178234-07193EC3-A29E-4F7F-8D84-D2C24AAF3900

Q37178234-41D987C7-A8B3-4219-A99A-6133C6007302

Q37178234-459A23DE-55BB-4B69-B9B8-43981F359F85

Q37178234-4C041E18-25BD-4BE9-BA7F-71D95CF881F4

Q37178234-5684E7D8-EEA0-4293-9243-BA095E680C98

Q37178234-7E41E082-0B47-4CAE-AFE1-67967B735B35

Q37178234-8A71E91F-C365-4237-A831-FB4044EFD015

Q37178234-AE00E1A4-8193-4CB2-8821-38631BB28D81

Q37178234-D87B948B-F9F5-44F2-8AF7-28FE99A54947

P304

Q37178234-14B33A14-A7BA-4CFB-9BB1-BEBB0ADADBD9

P31

Q37178234-BF0BA7B4-467A-498C-945C-C961600FD247

P356

Q37178234-2DBCEA71-01F9-4E3F-9E0D-3A237D36DCE2

P433

Q37178234-AF4CB2FE-6EBB-44DF-9322-74F0C1B055F4

P478

Q37178234-A436906B-EA2C-4A01-8C73-D45BBE019881

P50

Q37178234-5484ABA3-CEA8-447A-A35F-B925E4310CBB

Q37178234-5589255B-ABC8-47B4-9440-EA5D5A47DBCA

Q37178234-C3E5A4D5-CE10-4E21-8B28-D3F1B90830C1

P577

Q37178234-78F08370-F577-48F4-9EE9-1032F2010A66

P5875

Q37178234-FC82264C-4ABD-4396-B36A-BEAA164DD8E4

P698

Q37178234-29951EA0-7A9E-436D-8E6F-44B666BD9C3F

P921

Q37178234-0BAAF59F-3B6A-4F6E-892A-502A5F911BE0

P932

Q37178234-B2237357-746E-4C8C-9B5A-1E1F7B463ED3

P356

J.NUCMEDBIO.2007.12.008

P1433

Nuclear Medicine and Biology

P1476

Preclinical radioimmunotargeti ...... body conjugate DOTA-MORAb-003.

@en

P2093

Lloyd J Old

http://www.w3.org/2001/XMLSchema#string

Martin D Philips

http://www.w3.org/2001/XMLSchema#string

Neeta Pandit-Taskar

http://www.w3.org/2001/XMLSchema#string

Peter M Smith-Jones

http://www.w3.org/2001/XMLSchema#string

Steven M Larson

http://www.w3.org/2001/XMLSchema#string

Wei Cao

http://www.w3.org/2001/XMLSchema#string

P2860

The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?

Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects.

Macrocyclic chelates of radiometals for diagnosis and therapy.

Surface-specific iodination of membrane proteins of viruses and eucaryotic cells using 1,3,4,6-tetrachloro-3alpha,6alpha-diphenylglycoluril.

Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.

Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.

Biokinetics of the monoclonal antibodies MOv 18, OV 185 and OV 197 labelled with 125I according to the m-MeATE method or the Iodogen method in nude mice with ovarian cancer xenografts.

Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18.

Stable bifunctional chelates of metals used in radiotherapy.

P304

343-351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NUCMEDBIO.2007.12.008

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Jorge A. Carrasquillo

Joseph A O'Donoghue

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5496174

http://www.w3.org/2001/XMLSchema#string

P698

18355690

http://www.w3.org/2001/XMLSchema#string

P921

P932

2676680

http://www.w3.org/2001/XMLSchema#string